Research team discovered synergies between two developmental pathways responsible for tumor progression in glioblastoma, in the hopes of identifying future therapeutic avenues.
A leading brain tumor researcher explains how the transfer of mitochondria from astrocytes may fuel glioblastoma growth.
Glioblastoma cells use mitochondria from the central nervous system to grow and form more aggressive tumors, a new study finds. The finding suggests new opportunities for therapeutic development.
T-cell immunophenotyping sheds light on immune response to investigational SL-701-based therapy and promises to inform patient selection to maximize the likelihood of survival benefit.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
This novel approach involves injecting supercharged immune cells directly into the tumor cavity in the brain. Encouraging initial findings have set the stage for the launch of phase 2 testing.
Treatment of preclinical models of glioblastoma with a BACE1 inhibitor reprogrammed tumor-promoting macrophages into tumor-suppressing macrophages, destroying tumor cells in the process.
Hydrogen sulfide signaling emerged as a possible glioblastoma tumor suppressor that is highly sensitive to dysregulation by dietary fat. The findings suggest a potential role for dietary interventions that boost hydrogen sulfide bioavailability.
A preclinical study shows that inhibiting DNA-dependent protein kinase induces glioma stem cell differentiation and thereby sensitizes glioblastoma to radiation therapy.
Researchers are using low-frequency focused ultrasound with microbubble resonators to disrupt the blood-brain barrier and deliver chemotherapy to tumor cells in the brain.
Our latest Neuro Pathways podcast delves into glioblastoma research, touching on everything from single-cell RNA sequencing to sex differences and microbiome effects.